Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapy
Abstract In the muscle invasive bladder cancer (MIBC) standard of care treatment only patients presenting a major pathological tumor response are more likely to show the established modest 5% absolute survival benefit at 5 years after cisplatin-based neoadjuvant chemotherapy (NAC). To overcome the drawbacks of a blind NAC (i.e. late cystectomy with unnecessary NAC adverse events) with potential to survival improvements, preclinical models of urothelial carcinoma have arisen in this generation as a way to pre-determine drug resistance even before therapy is targeted. The implantation of tumor specimens in the chorioallantoic membrane (MCA) of the chicken embryo results in a high-efficiency graft, thus allowing large-scale studies of patient-derived “tumor avatar”. This article discusses a novel approach that exploits cancer multidrug resistance to provide personalized phenotype-based therapy utilizing the MIBC NAC dilemma.
Main Authors: | , , , , |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia
2019
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502019001200215 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
oai:scielo:S0102-86502019001200215 |
---|---|
record_format |
ojs |
spelling |
oai:scielo:S0102-865020190012002152020-02-07Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapyOssick,Marina VianFerrari,Karen LinaresNunes-Silva,IgorDenardi,FernandesReis,Leonardo Oliveira Chorioallantoic Membrane Urinary Bladder Neoplasms Heterografts Drug Therapy Abstract In the muscle invasive bladder cancer (MIBC) standard of care treatment only patients presenting a major pathological tumor response are more likely to show the established modest 5% absolute survival benefit at 5 years after cisplatin-based neoadjuvant chemotherapy (NAC). To overcome the drawbacks of a blind NAC (i.e. late cystectomy with unnecessary NAC adverse events) with potential to survival improvements, preclinical models of urothelial carcinoma have arisen in this generation as a way to pre-determine drug resistance even before therapy is targeted. The implantation of tumor specimens in the chorioallantoic membrane (MCA) of the chicken embryo results in a high-efficiency graft, thus allowing large-scale studies of patient-derived “tumor avatar”. This article discusses a novel approach that exploits cancer multidrug resistance to provide personalized phenotype-based therapy utilizing the MIBC NAC dilemma.info:eu-repo/semantics/openAccessSociedade Brasileira para o Desenvolvimento da Pesquisa em CirurgiaActa Cirúrgica Brasileira v.34 n.12 20192019-01-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502019001200215en10.1590/s0102-865020190120000007 |
institution |
SCIELO |
collection |
OJS |
country |
Brasil |
countrycode |
BR |
component |
Revista |
access |
En linea |
databasecode |
rev-scielo-br |
tag |
revista |
region |
America del Sur |
libraryname |
SciELO |
language |
English |
format |
Digital |
author |
Ossick,Marina Vian Ferrari,Karen Linares Nunes-Silva,Igor Denardi,Fernandes Reis,Leonardo Oliveira |
spellingShingle |
Ossick,Marina Vian Ferrari,Karen Linares Nunes-Silva,Igor Denardi,Fernandes Reis,Leonardo Oliveira Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapy |
author_facet |
Ossick,Marina Vian Ferrari,Karen Linares Nunes-Silva,Igor Denardi,Fernandes Reis,Leonardo Oliveira |
author_sort |
Ossick,Marina Vian |
title |
Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapy |
title_short |
Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapy |
title_full |
Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapy |
title_fullStr |
Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapy |
title_full_unstemmed |
Chorioallantoic urothelial tumor avatar. A clinical tool for phenotype-based therapy |
title_sort |
chorioallantoic urothelial tumor avatar. a clinical tool for phenotype-based therapy |
description |
Abstract In the muscle invasive bladder cancer (MIBC) standard of care treatment only patients presenting a major pathological tumor response are more likely to show the established modest 5% absolute survival benefit at 5 years after cisplatin-based neoadjuvant chemotherapy (NAC). To overcome the drawbacks of a blind NAC (i.e. late cystectomy with unnecessary NAC adverse events) with potential to survival improvements, preclinical models of urothelial carcinoma have arisen in this generation as a way to pre-determine drug resistance even before therapy is targeted. The implantation of tumor specimens in the chorioallantoic membrane (MCA) of the chicken embryo results in a high-efficiency graft, thus allowing large-scale studies of patient-derived “tumor avatar”. This article discusses a novel approach that exploits cancer multidrug resistance to provide personalized phenotype-based therapy utilizing the MIBC NAC dilemma. |
publisher |
Sociedade Brasileira para o Desenvolvimento da Pesquisa em Cirurgia |
publishDate |
2019 |
url |
http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-86502019001200215 |
work_keys_str_mv |
AT ossickmarinavian chorioallantoicurothelialtumoravataraclinicaltoolforphenotypebasedtherapy AT ferrarikarenlinares chorioallantoicurothelialtumoravataraclinicaltoolforphenotypebasedtherapy AT nunessilvaigor chorioallantoicurothelialtumoravataraclinicaltoolforphenotypebasedtherapy AT denardifernandes chorioallantoicurothelialtumoravataraclinicaltoolforphenotypebasedtherapy AT reisleonardooliveira chorioallantoicurothelialtumoravataraclinicaltoolforphenotypebasedtherapy |
_version_ |
1756401046924558336 |